Global Bipolar Disorder Therapeutics Units Market Size and Forecast 2024-2033 | AbbVie Inc., Pfizer Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb, GlaxoSmithKline PLC

The Bipolar Disorder Therapeutics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Bipolar Disorder Therapeutics Market:
https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report

According to The Business Research Company’s Bipolar Disorder Therapeutics Global Market Report 2024, The bipolar disorder therapeutics market size has grown strongly in recent years. It will grow from $7.09 billion in 2023 to $7.53 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rise in medical research and developments, increased healthcare expenditure, rise in prevalence of mental health disorders, rise in patient advocacy.

The bipolar disorder therapeutics market size is expected to see strong growth in the next few years. It will grow to $9.46 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing prevalence of bipolar disorder, government initiatives, expansion of healthcare infrastructure, growing adoption of a sedentary lifestyle. Major trends in the forecast period include personalized treatment approaches, digital health integration, innovative medications, preventive interventions, neuroimaging and biomarkers.

The increase in the prevalence of bipolar disorder is expected to propel the growth of the bipolar disorder therapeutics market going forward. Bipolar disorder refers to a disabling illness that is associated with depressive mood swings and includes symptoms such as irregular sleep, low motivation, and loss of interest in daily activities. Population growth and aging are leading to an increase in the burden of bipolar disorder over time. As a result, an increase in the prevalence of bipolar disorder increases the demand for the bipolar disorder therapeutics market. For instance, according to the Depression and Bipolar Support Alliance, a US-based non-profit association providing support to the patients of depression or bipolar disorder, in 2021, approximately 5.7 million adult Americans which was about 2.6% of the U.S. population were affected by bipolar disorder. The median age of the onset of bipolar disorder is 25 years, and more than two-thirds of people suffering from bipolar disorder had at least one relative with the illness. Therefore, the increase in the prevalence of bipolar disorder is driving the growth of the bipolar disorder therapeutics market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=6736&type=smp

The bipolar disorder therapeutics market covered in this report is segmented –

1) By Drug Class: Mood Stabilizers, Antipsychotic Drugs, Antidepressant Drugs, Other Drugs
2) By Mechanism: Selective Serotonin Reuptake Inhibitors, Serotonin-norepinephrine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Benzodiazepines, Beta-Blockers, Other Mechanisms
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Strategic partnerships have emerged as a key trend gaining popularity in the bipolar disorder therapeutics market. Major companies operating in the bipolar disorder therapeutics sector are focused on partnerships to reinforce their position. For instance, in October 2021, Mindpax Inc., a Germany-based digital technology company operating in the bipolar disorder therapeutics market, partnered with Eversana Life Science Services LLC, a US-based life sciences company operating in the bipolar disorder therapeutics market. Through this partnership, both companies will develop remote clinical assessments and targeted digital therapy to improve patients’ clinical conditions and provide personalized therapeutic interventions to bipolar patients. Furthermore, in November 2020, Biogen, a US-based biotechnology company, partnered with Sage Therapeutics, a US-based company that develops novel therapies including bipolar. Through this partnership, both businesses will work together to commercialize zuranolone (SAGE-217) for significant postpartum depression (PPD), depressive disorder (MDD), and other psychiatric diseases.

The bipolar disorder therapeutics market report table of contents includes:

1. Executive Summary

2. Bipolar Disorder Therapeutics Market Characteristics

3. Bipolar Disorder Therapeutics Market Trends And Strategies

4. Bipolar Disorder Therapeutics Market – Macro Economic Scenario

5. Global Bipolar Disorder Therapeutics Market Size and Growth

…

31. Global Bipolar Disorder Therapeutics Market Competitive Benchmarking

32. Global Bipolar Disorder Therapeutics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Bipolar Disorder Therapeutics Market

34. Bipolar Disorder Therapeutics Market Future Outlook and Potential Analysis

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model